Prevalence and factors associated with carriage of Pfmdr1 polymorphisms among pregnant women receiving intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp-SP) and artemether-lumefantrine for malaria treatment in Burkina Faso
Hamtandi Magloire Natama(Research Institute of Health Sciences), Fati Kirakoya‐Samadoulougou(Johns Hopkins University), Halidou Tinto(Institut de Recherche en Sciences de la Santé), Toussaint Rouamba(Institut de Recherche en Sciences de la Santé), Maminata Coulibaly-Traoré(Institut de Recherche en Sciences de la Santé), Sékou Samadoulougou(Université Laval), Djamina Line Cerine Bazié(Institut de Recherche en Sciences de la Santé)
Cited by 3
Related Papers
Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial
|The Lancet|2021|457
Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine
|New England Journal of Medicine|2015|451
Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial
|The Lancet|2024|345